Stocktoria
Candel Therapeutics, Inc. CADL
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-07-27
Candel Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $125,000 | $125,000 |
| R&D expense | $30.5M | $19.3M | $24.5M | $20.8M | $15.2M |
| Operating income | -$48.3M | -$33.4M | -$38.4M | -$34.7M | -$25.7M |
| Interest expense | $2.1M | $2.1M | -$2.6M | $1.7M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$38.2M | -$55.2M | -$37.9M | -$18.8M | -$36.1M |
| EPS (diluted) | $-0.72 | $-1.74 | $-1.31 | $-0.65 | $-1.91 |
| Operating cash flow | -$38.3M | -$27.0M | -$34.2M | -$31.4M | -$22.2M |
| Free cash flow | -$38.9M | -$27.0M | -$34.7M | -$32.7M | -$24.1M |
| Cash & equivalents | $119.7M | $102.7M | $35.4M | $70.1M | $82.6M |
| Total assets | $125.2M | $106.9M | $41.2M | $77.7M | $89.2M |
| Total liabilities | $73.3M | $40.5M | $28.5M | $30.0M | $25.1M |
| Shareholders' equity | $51.9M | $66.3M | $12.7M | $47.7M | $64.1M |
Source: SEC EDGAR filings · CIK 0001841387 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.